Transcode Therapeutics Inc   (RNAZ)
Other Ticker:  
Price: $0.7102 $0.02 3.302%
Day's High: $0.744 Week Perf: 4.59 %
Day's Low: $ 0.69 30 Day Perf: -2.86 %
Volume (M): 863 52 Wk High: $ 309.60
Volume (M$): $ 613 52 Wk Avg: $38.25
Open: $0.70 52 Wk Low: $0.14

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Transcode Therapeutics Inc
Transcode Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative RNA therapeutics. They focus on creating cutting-edge treatments for various diseases by harnessing the power of mRNA and related technologies.

Transcode Therapeutics utilizes its proprietary platform to design and optimize novel RNA therapeutics, including mRNA vaccines, mRNA-based gene therapies, and RNAi therapeutics. Their approach allows for precise targeting and modulation of disease-causing genes and proteins, offering potential solutions for a wide range of medical conditions.

The company aims to revolutionize the field of medicine by leveraging the versatility of RNA molecules to develop safe and effective therapies. Through their research and development efforts, Transcode Therapeutics is dedicated to advancing the understanding and application of RNA in the treatment of diseases, ultimately improving patient outcomes and quality of life.

   Company Address: 6 Liberty Square, #2382 Boston 2109 MA
   Company Phone Number: 837-3099   Stock Exchange / Ticker: NASDAQ RNAZ
   RNAZ is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Revitalizing the Fight Against Metastatic Pancreatic Cancer: TransCode Therapeutics Unveils Groundbreaking Results with TTX-MC138

Published Tue, Dec 12 2023 1:30 PM UTC

TransCode Therapeutics, a prominent biopharmaceutical company specializing in the development of innovative therapies, has recently reported positive pre-clinical results for its lead candidate, TTX-MC138. This groundbreaking research demonstrates the effectiveness of TTX-MC138 in animal models of human metastatic pancreatic cancer. In this article, we will outlin...

Clinical Study

TransCode Therapeutics Unveils Revolutionary RNA Therapy for Breast Cancer: Promising Phase 0 Data Revealed at San Antonio Symposium

Published Tue, Dec 5 2023 2:02 PM UTC

TransCode Therapeutics, a leading RNA oncology company, is set to unveil exciting new data from the Phase 0 clinical trial of its revolutionary RNA therapeutic, TTX-MC138. As the company's lead candidate in cancer therapy, TTX-MC138 has demonstrated immense potential in more effectively treating breast cancer. This groundbreaking development will be presented at th...

Financing Agreement

TransCode Therapeutics Raises $9.7 Million to Catapult Cancer Treatment into the RNA Revolution

Published Mon, Dec 4 2023 9:10 PM UTC

TransCode Therapeutics Raises $9.7 Million in Capital to Accelerate Breakthroughs in RNA Oncology
TransCode Therapeutics, a leading RNA oncology company dedicated to transforming cancer treatment through innovative RNA therapeutics, recently announced the closing of two successful funding rounds. The company successfully completed a registered direct offering, generating...

Stock Market Announcement

TransCode Therapeutics Announces Registered Direct Offering, Further Strengthening Commitment to Advancements in RNA Oncology

Published Thu, Nov 30 2023 7:53 PM UTC

In a promising move towards developing more effective cancer treatments, TransCode Therapeutics, Inc. (Nasdaq: RNAZ) revealed today that it has entered into a definitive securities purchase agreement for the sale and purchase of 5,000,000 shares of common stock. Priced at $0.242 per share of common stock, this registered direct offering, in compliance with Nasdaq rules,...

Transcode Therapeutics Inc

Transcode Therapeutics Inc's Fiscal Period Sees Decline in Company Results2.

Transcode Therapeutics Inc: An Optimistic Outlook for the Future
As the earning season for the Major Pharmaceutical Preparations industry unfolds, Transcode Therapeutics Inc stands out with its recently disclosed operating shortfall of $-5.327534 million for the period. While the figure may seem discouraging at first glance, it is important to note the contraction from the previous quarter's operating shortfall of $-4.95356 million.
Market participants are now left wondering if Transcode Therapeutics Inc will be able to generate revenue in the near future. The company, however, remains confident as it implements various business strategies to ensure steady growth. Despite the shortfalls experienced during the developing stage, Transcode Therapeutics Inc has shown resilience, with shortfalls extending to $-5.300 million from $-4.290 million in the third quarter of 2022.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com